Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib Effect on Midazolam PK
NCT04187456Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of savolitinib in solid tumor, sponsored by AstraZeneca. Primary endpoints: Area under the plasma concentration-time curve ratio (Midazolam + Savolitinib / Midazolam alone) at Day 5 and Maximum observed plasma concentration ratio (Midazolam + Savolitinib / Midazolam alone) at Day 5. Started Dec 2019; status: completed.
02
Drugs
savolitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04187456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187456.